- Home
- OPRT vs PRTA Comparison
OPRT vs PRTA Comparison
Compare OPRT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- PRTA
- Stock Information
- Founded
- OPRT 2005
- PRTA 2012
- Country
- OPRT United States
- PRTA Ireland
- Employees
- OPRT N/A
- PRTA N/A
- Industry
- OPRT Finance: Consumer Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- OPRT Finance
- PRTA Health Care
- Exchange
- OPRT Nasdaq
- PRTA Nasdaq
- Market Cap
- OPRT 298.8M
- PRTA 346.4M
- IPO Year
- OPRT 2019
- PRTA N/A
- Fundamental
- Price
- OPRT $6.78
- PRTA $6.41
- Analyst Decision
- OPRT Hold
- PRTA Buy
- Analyst Count
- OPRT 2
- PRTA 9
- Target Price
- OPRT $8.00
- PRTA $27.67
- AVG Volume (30 Days)
- OPRT 804.8K
- PRTA 1.7M
- Earning Date
- OPRT 08-07-2025
- PRTA 08-07-2025
- Dividend Yield
- OPRT N/A
- PRTA N/A
- EPS Growth
- OPRT N/A
- PRTA N/A
- EPS
- OPRT N/A
- PRTA N/A
- Revenue
- OPRT $746,101,000.00
- PRTA $137,935,000.00
- Revenue This Year
- OPRT $28.61
- PRTA N/A
- Revenue Next Year
- OPRT $7.22
- PRTA $122.02
- P/E Ratio
- OPRT N/A
- PRTA N/A
- Revenue Growth
- OPRT N/A
- PRTA 54.55
- 52 Week Low
- OPRT $2.37
- PRTA $4.32
- 52 Week High
- OPRT $9.25
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- OPRT 48.05
- PRTA 57.61
- Support Level
- OPRT $6.88
- PRTA $5.96
- Resistance Level
- OPRT $7.26
- PRTA $6.77
- Average True Range (ATR)
- OPRT 0.52
- PRTA 0.36
- MACD
- OPRT -0.05
- PRTA 0.14
- Stochastic Oscillator
- OPRT 27.96
- PRTA 75.80
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.